ASPE Stock Forecast: Aspen Neuroscience, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 0 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Aspen Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (20): Analysts have, on balance, been raising their forecasts.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ASPE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ASPE, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
ASPE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ASPE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- —
- Dividend yield
- —
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aspen Neuroscience, Inc. has a market value of $361.2M and an enterprise value of $637.4M.
Aspen Neuroscience, Inc. employs 120 people.
Data provided by Twelve Data
ASPE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ASPE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Aspen Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ASPE
How does Ticker Nerd's model rank ASPE?
As at 21 Nov 2026, Aspen Neuroscience, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (20 of 100).
What is the ASPE stock forecast for 2030?
No analyst covering Aspen Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASPE are extrapolating price history, which says nothing about the business.
What does Aspen Neuroscience, Inc. do?
Aspen Neuroscience, Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies for neurodegenerative diseases. Its core platform uses a patient’s own cells to create induced pluripotent stem cells, which are differentiated into specialized neural cells intended to replace or support damaged tissue.
About Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies for neurodegenerative diseases. Its core platform uses a patient’s own cells to create induced pluripotent stem cells, which are differentiated into specialized neural cells intended to replace or support damaged tissue. The company’s leading investigational product, sasineprocel, is an autologous, single-dose cell therapy being evaluated for Parkinson’s disease. Aspen Neuroscience focuses on personalized approaches that may help address neurological conditions involving the loss or dysfunction of specific cell types. Its activities span cell biology, stem-cell manufacturing, translational research, and clinical development, positioning the company within the regenerative medicine and advanced therapies sectors. Headquartered in San Diego, California, Aspen Neuroscience serves the biotechnology and healthcare markets by developing patient-specific treatments for disorders with substantial unmet medical needs. Its work reflects the growing role of autologous cell-based platforms in precision medicine and neurological disease research.
CEO Dr. Damien McDevitt Ph.D. · 120 employees · United States · https://www.aspenneuroscience.com